Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
10 results
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 11 2 2024, Pages ezae157 Glenn shunt as a rescue strategy for acute right ventricular failure after right ventricular myocardial infarction. den Haan MC, Palmen M, Egorova AD, Hazekamp MG
We present a case of a 52-year old woman with cardiogenic shock (CS) with refractory right ventricular (RV) failure due to spontaneous dissection of the right coronary artery (RCA). She remained dependent on mechanical support for several weeks and both RV assist device (RVAD) implantation and bidirectional cavopulmonary anastomosis (BCPA) were explored as long-term support options. History of malignancy and possible RV functional recovery resulted in a decision in favour of BCPA and concomitant... Abstract
Learning health systems, Volume 8, Issue 1, 15 3 2023, Pages e10379 Learning healthcare systems in cardiology: A qualitative interview study on ethical dilemmas of a learning healthcare system. Laurijssen S, van der Graaf R, Schuit E, den Haan M, van Dijk W, Groenwold R, le Sessie S, Grobbee D, de Vries M
Background: Implementation of an LHS in cardiology departments presents itself with ethical challenges, including ethical review and informed consent. In this qualitative study, we investigated stakeholders' attitudes toward ethical issues regarding the implementation of an LHS in the cardiology department. Methods: We conducted a qualitative study using 35 semi-structured interviews and 5 focus group interviews with 34 individuals. We interviewed cardiologists, research nurses, cardiovascu... Abstract
Cited 1 times since 2023 (0.9 per year) source: EuropePMC
Genes, Volume 14, Issue 3, 25 4 2023, Pages 578 Feasibility of Community Pharmacist-Initiated and Point-of-Care <i>CYP2C19</i> Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors. Levens AD, den Haan MC, Jukema JW, Heringa M, van den Hout WB, Moes DJAR, Swen JJ
Tailoring antiplatelet therapy based on CYP2C19 pharmacogenetic (PGx) testing can improve cardiovascular outcomes and potentially reduce healthcare costs in patients on a P2Y12-inhibitor regime with prasugrel or ticagrelor. However, ubiquitous adoption-particularly in an outpatient setting-remains limited. We conducted a proof-of-concept study to evaluate the feasibility of CYP2C19-guided de-escalation of prasugrel/ticagrelor to clopidogrel through point-of-care (POC) PGx testing in the communit... Abstract
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, Volume 30, Issue 9, 11 2 2022, Pages 431-435 Emergency Heart failure Mortality Risk Grade may help to reduce heart failure admissions. van Hattem NE, Beeres SLMA, Mertens BJA, Antoni ML, Atsma DE, Schalij MJ, den Haan MC
Introduction: Hospital admissions for heart failure (HF) are frequent and pose a heavy burden on health care resources. Currently, the decision to hospitalise is based on clinical judgement rather than on prognostic risk stratification. The Emergency Heart failure Mortality Risk Grade (EHMRG) was recently developed to identify high-risk HF patients in the emergency department (ED). Objective: To assess the ability of the EHMRG to predict 30-day mortality in Dutch HF patients visiting the ED and... Abstract
Cited 8 times since 2021 (2.8 per year) source: EuropePMC
Frontiers in public health, Volume 9, 16 3 2021, Pages 568822 Creating a Social Learning Environment for and by Older Adults in the Use and Adoption of Smartphone Technology to Age in Place. den Haan M, Brankaert R, Kenning G, Lu Y
Smartphone technologies can support older adults in their daily lives as they age in place at home. However, they may struggle to use these technologies which impacts acceptance, adoption, and sustainable use. Peer to peer community learning has the potential to support older adults to learn using (smartphone) technologies. This paper studies such a learning community approach and how it can support older adults to learn using and adopt the smartphone application GoLivePhone. This technology ass... Abstract
Cited 10 times since 2019 (2.1 per year) source: EuropePMC
PloS one, Volume 14, Issue 6, 14 2 2019, Pages e0217582 Hypercholesterolemia affects cardiac function, infarct size and inflammation in APOE*3-Leiden mice following myocardial ischemia-reperfusion injury. Pluijmert NJ, den Haan MC, van Zuylen VL, Steendijk P, de Boer HC, van Zonneveld AJ, Fibbe WE, Schalij MJ, Quax PHA, Atsma DE
Background: Hypercholesterolemia is a major risk factor for ischemic heart disease including acute myocardial infarction. However, long-term effects of hypercholesterolemia in a rodent myocardial ischemia-reperfusion injury model are unknown. Therefore, the effects of diet-induced hypercholesterolemia on cardiac function and remodeling were investigated up to eight weeks after myocardial ischemia-reperfusion (MI-R) injury which was induced in either normocholesterolemic (NC-MI) or hypercholester... Abstract
Cited 4 times since 2016 (0.5 per year) source: EuropePMC
PloS one, Volume 11, Issue 4, 6 1 2016, Pages e0152938 Discrepant Results of Experimental Human Mesenchymal Stromal Cell Therapy after Myocardial Infarction: Are Animal Models Robust Enough? den Haan MC, van Zuylen VL, Pluijmert NJ, Schutte CI, Fibbe WE, Schalij MJ, Roelofs H, Atsma DE
Background: Human mesenchymal stromal cells (MSCs) have been reported to preserve cardiac function in myocardial infarction (MI) models. Previously, we found a beneficial effect of intramyocardial injection of unstimulated human MSCs (uMSCs) on cardiac function after permanent coronary artery ligation. In the present study we aimed to extend this research by investigating the effect of intramyocardial injection of human MSCs pre-stimulated with the pro-inflammatory cytokine interferon-gamma (iMS... Abstract
Cited 9 times since 2015 (1 per year) source: EuropePMC
SpringerPlus, Volume 4, 10 2 2015, Pages 336 Myocardial infarction models in NOD/Scid mice for cell therapy research: permanent ischemia vs ischemia-reperfusion. van Zuylen VL, den Haan MC, Roelofs H, Fibbe WE, Schalij MJ, Atsma DE
Myocardial infarction animal studies are used to study disease mechanisms and new treatment options. Typically, myocardial infarction (MI) is induced by permanent occlusion of the left anterior descending artery. Since in MI patients coronary blood flow is often restored new experimental models better reflecting clinical practice are needed. Here, permanent ischemia MI (PI group) was compared with transient ischemia (45 min) (IR group) in immunodeficient NOD/Scid mice. Cardiac function, infarct... Abstract
Cited 13 times since 2015 (1.4 per year) source: EuropePMC
Cardiovascular drugs and therapy, Volume 29, Issue 1, 1 1 2015, Pages 59-73 Post-myocardial infarct inflammation and the potential role of cell therapy. van Zuylen VL, den Haan MC, Geutskens SB, Roelofs H, Fibbe WE, Schalij MJ, Atsma DE
Myocardial infarction triggers reparative inflammatory processes programmed to repair damaged tissue. However, often additional injury to the myocardium occurs through the course of this inflammatory process, which ultimately can lead to heart failure. The potential beneficial effects of cell therapy in treating cardiac ischemic disease, the number one cause of death worldwide, are being studied extensively, both in clinical trials using adult stem cells as well as in fundamental research on car... Abstract
Cited 26 times since 2012 (2.2 per year) source: EuropePMC
Journal of cellular and molecular medicine, Volume 16, Issue 7, 1 1 2012, Pages 1508-1521 Cardiomyogenic differentiation-independent improvement of cardiac function by human cardiomyocyte progenitor cell injection in ischaemic mouse hearts. den Haan MC, Grauss RW, Smits AM, Winter EM, van Tuyn J, Pijnappels DA, Steendijk P, Gittenberger-De Groot AC, van der Laarse A, Fibbe WE, de Vries AA, Schalij MJ, Doevendans PA, Goumans MJ, Atsma DE
We previously showed that human cardiomyocyte progenitor cells (hCMPCs) injected after myocardial infarction (MI) had differentiated into cardiomyocytes in vivo 3 months after MI. Here, we investigated the short-term (2 weeks) effects of hCMPCs on the infarcted mouse myocardium. MI was induced in immunocompromised (NOD/scid) mice, immediately followed by intramyocardial injection of hCMPCs labelled with enhanced green fluorescent protein (hCMPC group) or vehicle only (control group). Sham-operat... Abstract